201 related articles for article (PubMed ID: 17108215)
1. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia.
Müller I; Urban K; Pantel K; Schwarzenbach H
Ann N Y Acad Sci; 2006 Sep; 1075():222-9. PubMed ID: 17108215
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
Schwarzenbach H; Chun FK; Müller I; Seidel C; Urban K; Erbersdobler A; Huland H; Pantel K; Friedrich MG
BJU Int; 2008 Jul; 102(2):253-8. PubMed ID: 18336598
[TBL] [Abstract][Full Text] [Related]
3. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
Schwarzenbach H; Müller V; Stahmann N; Pantel K
Ann N Y Acad Sci; 2004 Jun; 1022():25-32. PubMed ID: 15251935
[TBL] [Abstract][Full Text] [Related]
4. Detection of Loss of Heterozygosity (LOH) Using Circulating Cell-free DNA (cfDNA) by Fluorescence-based Multiplex PCR for Identification of Patients With Prostate Cancer.
Seyedolmohadessin SM; Akbari MT; Nourmohammadi Z; Basiri A; Pourmand G
Appl Immunohistochem Mol Morphol; 2018; 26(10):749-759. PubMed ID: 28362710
[TBL] [Abstract][Full Text] [Related]
5. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
6. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients.
Bryzgunova OE; Morozkin ES; Yarmoschuk SV; Vlassov VV; Laktionov PP
Ann N Y Acad Sci; 2008 Aug; 1137():222-5. PubMed ID: 18837951
[TBL] [Abstract][Full Text] [Related]
7. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.
Fromont G; Valeri A; Cher M; Pontes JE; Vallancien G; Validire P; Latil A; Cussenot O
Prostate; 2005 Dec; 65(4):341-6. PubMed ID: 16015610
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity on chromosome 2 in Japanese patients with prostate cancer.
Ueda T; Komiya A; Suzuki H; Shimbo M; Sakamoto S; Imamoto T; Akakura K; Shiraishi T; Ichikawa T
Prostate; 2005 Aug; 64(3):265-71. PubMed ID: 15717310
[TBL] [Abstract][Full Text] [Related]
9. LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13.
Fiedler U; Ehlers W; Meye A; Füssel S; Faller G; Schmidt U; Wirth MP
Anticancer Res; 2001; 21(4A):2341-50. PubMed ID: 11724291
[TBL] [Abstract][Full Text] [Related]
10. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
[TBL] [Abstract][Full Text] [Related]
11. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer.
Jung K; Stephan C; Lewandowski M; Klotzek S; Jung M; Kristiansen G; Lein M; Loening SA; Schnorr D
Cancer Lett; 2004 Mar; 205(2):173-80. PubMed ID: 15036649
[TBL] [Abstract][Full Text] [Related]
12. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients.
Taback B; Fujiwara Y; Wang HJ; Foshag LJ; Morton DL; Hoon DS
Cancer Res; 2001 Aug; 61(15):5723-6. PubMed ID: 11479206
[TBL] [Abstract][Full Text] [Related]
15. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
Schwarzenbach H; Chun FK; Lange I; Carpenter S; Gottberg M; Erbersdobler A; Friedrich MG; Huland H; Pantel K
Int J Cancer; 2007 Apr; 120(7):1465-71. PubMed ID: 17205532
[TBL] [Abstract][Full Text] [Related]
16. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
Allen D; Butt A; Cahill D; Wheeler M; Popert R; Swaminathan R
Ann N Y Acad Sci; 2004 Jun; 1022():76-80. PubMed ID: 15251943
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Talesa VN; Antognelli C; Del Buono C; Stracci F; Serva MR; Cottini E; Mearini E
Cancer Biomark; 2009; 5(6):241-51. PubMed ID: 20037200
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
Chuang CK; Chu DC; Tzou RD; Liou SI; Chia JH; Sun CF
Cancer Detect Prev; 2007; 31(1):59-63. PubMed ID: 17291695
[TBL] [Abstract][Full Text] [Related]
19. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements.
Müller I; Beeger C; Alix-Panabières C; Rebillard X; Pantel K; Schwarzenbach H
Clin Chem; 2008 Apr; 54(4):688-96. PubMed ID: 18281424
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profile in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.
Alonso V; Neves AF; Marangoni K; Faria PC; Freschi AP; Capaneli AC; Meola J; Goulart LR
Cancer Detect Prev; 2009; 32(4):336-7. PubMed ID: 19026495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
